Neophytos Kouphou
A5026262746- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Long-Term Effects of COVID-19
- Animal Virus Infections Studies
- Biosensors and Analytical Detection
- Adipokines, Inflammation, and Metabolic Diseases
- Influenza Virus Research Studies
- Cardiovascular Disease and Adiposity
- Respiratory viral infections research
- COVID-19 epidemiological studies
- Viral gastroenteritis research and epidemiology
King's College London
2020-2023
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due recent emergence human population, it is not known how long antibody will maintained or whether they provide protection from reinfection. Using sequential serum samples collected up 94 post symptoms (POS) 65 with real-time quantitative PCR-confirmed infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) >95% cases and neutralizing when sampled...
Abstract Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due recent emergence this virus human population it is not yet known how long these Ab will maintained or whether they provide protection from re-infection. Using sequential serum samples collected up 94 post symptoms (POS) 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion >95% cases and neutralizing antibody...
Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with ACE2 on host cells is essential for viral entry. RBD dominant target neutralizing antibodies, and several epitopes have been molecularly characterized. Analysis circulating variants has revealed mutations arising in RBD, N-terminal (NTD) S2 subunits Spike. To understand how these affect antigenicity, we isolated characterized >100 monoclonal antibodies targeting NTD, from SARS-CoV-2-infected individuals. Approximately 45%...
COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability cross-neutralizing potential against SARS-CoV-2 emerging variants concern (VOCs). Analyses convalescent sera provide unique insights longevity activity induced by variant spike proteins, which are putative candidates. Using from 38 individuals infected in wave 1, we show that can be detected up 305 days pos onset symptoms, although were less potent B.1.1.7 (Alpha) B1.351...
There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as complement to existing diagnostic capabilities and determining community seroprevalence. We therefore evaluated the performance of variety testing technologies their potential use tools. Highly specific in-house ELISAs were developed detection anti-spike (S), -receptor binding domain (RBD) -nucleocapsid (N) antibodies used cross-comparison ten commercial serological assays—a chemiluminescence-based platform, two...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels can be used to assess humoral immune responses following SARS-CoV-2 infection or vaccination, and may predict risk of future infection. Higher anti-Spike antibodies are known associated with increased protection against However, variation in factors for lower each round vaccination have not been explored across a wide range socio-demographic, health within population-based cohorts.
Understanding of the true asymptomatic rate infection SARS-CoV-2 is currently limited, as understanding population-based seroprevalence after first wave COVID-19 within UK. The majority data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms.We undertook enzyme linked immunosorbent assay characterisation IgM and IgG responses against spike glycoprotein nucleocapsid protein 431 unselected general-population participants TwinsUK cohort...
The interaction of the SARS–CoV–2 Spike receptor binding domain (RBD) with ACE2 on host cells is essential for viral entry. RBD dominant target neutralizing antibodies and several epitopes have been molecularly characterized. Analysis circulating variants has revealed mutations arising in RBD, N–terminal (NTD) S2 subunits Spike. To fully understand how these affect antigenicity Spike, we isolated characterized targeting beyond already identified epitopes. Using recombinant as a sorting bait,...
Abstract There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as complement to existing diagnostic capabilities and determining community seroprevalence. We therefore evaluated the performance of variety testing technologies their potential tools. A highly specific in-house ELISA was developed detection anti-spike (S), -receptor binding domain (RBD) -nucleocapsid (N) antibodies used cross-comparison ten commercial serological assays – chemiluminescence-based platform,...
Abstract Background Understanding of the true asymptomatic rate infection SARS-CoV-2 is currently limited, as understanding population-based seroprevalence after first wave COVID-19 within UK. The majority data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods We undertook enzyme linked immunosorbent assay characterisation IgM and IgG responses against spike glycoprotein nucleocapsid protein 431 unselected general-population...
During the first wave of global COVID-19 pandemic clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy assays required rapid evaluation their performance characteristics. We undertook an internal validation a CE marked lateral flow immunoassay (LFIA) (SureScreen Diagnostics) using serum from RNA positive individuals pre-pandemic samples. This was followed by delivery same-day named patient serology service LFIA on vetted...
As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19 vaccination is the generation of durable antibody response with cross-neutralizing activity against both current and newly emerging viral variants. Cross-neutralizing concern (B.1.1.7, P.1 B.1.351) has been observed following vaccination, albeit at reduced potency, but whether vaccines based on Spike glycoprotein these will produce superior not fully investigated. Here, we used sera from individuals infected...
ABSTRACT OBJECTIVE Determine indications and clinical utility of SARS-CoV-2 serology testing in adults children. DESIGN Prospective evaluation initial three weeks a daily Monday to Friday pilot service for patients. SETTING Early post “first-wave” transmission period at single centre London teaching hospital that provides care the local community, as well regional national referral pathways specialist services. PARTICIPANTS 110 (72 adults, 38 children, age range 0-83 years, 52.7% female...
Abstract SARS-CoV-2 antibody levels can be used to assess humoral immune responses following infection or vaccination, and may predict risk of future infection. From cross-sectional testing 9,361 individuals from TwinsUK ALSPAC UK population-based longitudinal studies (jointly in April-May 2021, only November 2021-January 2022), we tested associations between vaccination and: (1) vaccination(s); (2) health, socio-demographic, variables. Within TwinsUK, single-vaccinated with the lowest 20%...